{"id":41795,"date":"2025-09-18T15:23:25","date_gmt":"2025-09-18T07:23:25","guid":{"rendered":"https:\/\/flcube.com\/?p=41795"},"modified":"2025-09-18T15:23:26","modified_gmt":"2025-09-18T07:23:26","slug":"jiangsu-hengrui-hrs%e2%80%915635-seeks-breakthrough-therapy-designation-for-chronic-hepatitis-b","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41795","title":{"rendered":"Jiangsu Hengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that its next\u2011generation small\u2011interfering RNA (siRNA) drug, <strong>HRS\u20115635 injection<\/strong>, has been <strong>proposed for inclusion in the Breakthrough Therapy Designation (BTD) list<\/strong> by the <strong>Center for Drug Evaluation (CDE)<\/strong> of China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>. The move could fast\u2011track the approval of a potentially disease\u2011modifying therapy for chronic hepatitis\u202fB (CHB).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-hrs-5635\">What is HRS\u20115635?<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Liver\u2011targeted siRNA<\/strong> engineered to silence hepatitis\u202fB virus (HBV) genes.<\/li>\n\n\n\n<li>Developed <strong>independently by Hengrui Pharma<\/strong> using proprietary delivery technology that enhances hepatic uptake and reduces off\u2011target effects.<\/li>\n\n\n\n<li><strong>Phase\u202fII data<\/strong> show HRS\u20115635 monotherapy may <strong>increase the functional cure rate<\/strong> of CHB while maintaining a favorable safety profile.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-btd-matters\">Why BTD Matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BTD status<\/strong> gives the drug priority review, accelerated assessment, and potential for priority marketing approval in China.<\/li>\n\n\n\n<li>No <strong>domestic or international<\/strong> siRNA therapy for HBV has yet received regulatory approval, positioning HRS\u20115635 as a first\u2011in\u2011class candidate.<\/li>\n\n\n\n<li>A BTD designation would also signal to global investors and partners a strong regulatory endorsement, potentially opening avenues for international collaboration.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook\">Market Outlook<\/h2>\n\n\n\n<p>China alone accounts for <strong>&gt;\u202f30\u202f% of the global CHB patient population<\/strong>. If approved, HRS\u20115635 could capture a significant share of a market projected to exceed <strong>$10\u202fbillion<\/strong> by 2030. The drug\u2019s unique mechanism and early\u2011stage data may also attract interest from U.S. and EU regulators, accelerating its global footprint.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investor-takeaway\">Investor Takeaway<\/h2>\n\n\n\n<p>Jiangsu\u202fHengrui\u2019s pursuit of BTD for HRS\u20115635 underscores its commitment to innovation in virology and positions the company as a serious contender in the rapidly expanding antiviral therapeutics arena.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next\u2011generation small\u2011interfering RNA&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41796,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,2586,4228,64,852,89],"class_list":["post-41795","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-rnai-aso","tag-sha-600276","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Hengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next\u2011generation small\u2011interfering RNA (siRNA) drug, HRS\u20115635 injection, has been proposed for inclusion in the Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The move could fast\u2011track the approval of a potentially disease\u2011modifying therapy for chronic hepatitis\u202fB (CHB).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41795\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Hengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next\u2011generation small\u2011interfering RNA (siRNA) drug, HRS\u20115635 injection, has been proposed for inclusion in the Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The move could fast\u2011track the approval of a potentially disease\u2011modifying therapy for chronic hepatitis\u202fB (CHB).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41795\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-18T07:23:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-18T07:23:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1806.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41795#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41795\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Hengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB\",\"datePublished\":\"2025-09-18T07:23:25+00:00\",\"dateModified\":\"2025-09-18T07:23:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41795\"},\"wordCount\":277,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41795#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1806.webp\",\"keywords\":[\"Breakthrough therapy\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"RNAi \\\/ ASO\",\"SHA: 600276\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41795#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41795\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41795\",\"name\":\"Jiangsu Hengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41795#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41795#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1806.webp\",\"datePublished\":\"2025-09-18T07:23:25+00:00\",\"dateModified\":\"2025-09-18T07:23:26+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next\u2011generation small\u2011interfering RNA (siRNA) drug, HRS\u20115635 injection, has been proposed for inclusion in the Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The move could fast\u2011track the approval of a potentially disease\u2011modifying therapy for chronic hepatitis\u202fB (CHB).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41795#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41795\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41795#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1806.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1806.webp\",\"width\":1080,\"height\":608,\"caption\":\"Jiangsu\u202fHengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41795#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Hengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Hengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next\u2011generation small\u2011interfering RNA (siRNA) drug, HRS\u20115635 injection, has been proposed for inclusion in the Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The move could fast\u2011track the approval of a potentially disease\u2011modifying therapy for chronic hepatitis\u202fB (CHB).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41795","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Hengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next\u2011generation small\u2011interfering RNA (siRNA) drug, HRS\u20115635 injection, has been proposed for inclusion in the Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The move could fast\u2011track the approval of a potentially disease\u2011modifying therapy for chronic hepatitis\u202fB (CHB).","og_url":"https:\/\/flcube.com\/?p=41795","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-18T07:23:25+00:00","article_modified_time":"2025-09-18T07:23:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1806.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41795#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41795"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Hengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB","datePublished":"2025-09-18T07:23:25+00:00","dateModified":"2025-09-18T07:23:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41795"},"wordCount":277,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41795#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1806.webp","keywords":["Breakthrough therapy","Hengrui Pharmaceuticals","HKG: 1276","RNAi \/ ASO","SHA: 600276","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41795#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41795","url":"https:\/\/flcube.com\/?p=41795","name":"Jiangsu Hengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41795#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41795#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1806.webp","datePublished":"2025-09-18T07:23:25+00:00","dateModified":"2025-09-18T07:23:26+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next\u2011generation small\u2011interfering RNA (siRNA) drug, HRS\u20115635 injection, has been proposed for inclusion in the Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA). The move could fast\u2011track the approval of a potentially disease\u2011modifying therapy for chronic hepatitis\u202fB (CHB).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41795#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41795"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41795#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1806.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1806.webp","width":1080,"height":608,"caption":"Jiangsu\u202fHengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41795#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Hengrui HRS\u20115635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis\u202fB"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1806.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41795"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41795\/revisions"}],"predecessor-version":[{"id":41798,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41795\/revisions\/41798"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41796"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}